Raid Aljumaily
Overview
Explore the profile of Raid Aljumaily including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, et al.
Nat Med
. 2025 Jan;
31(1):152-164.
PMID: 39762422
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from...
2.
Sen T, Dotsu Y, Corbett V, Puri S, Sen U, Boyle T, et al.
Lancet Oncol
. 2025 Jan;
26(1):e13-e33.
PMID: 39756451
Lung neuroendocrine neoplasms are a group of diverse, heterogeneous tumours that range from well-differentiated, low-grade neuroendocrine tumours-such as typical and atypical carcinoids-to high-grade, poorly differentiated aggressive malignancies, such as large-cell...
3.
Popuri N, Nagalapuram V, Zaman U, Aljumaily R
Case Rep Oncol
. 2024 Nov;
17(1):1329-1334.
PMID: 39574542
Background: Non-small cell lung cancer (NSCLC) accounts for 84% of all lung cancers and continues to remain the leading cause of cancer-related mortality worldwide. The advent of gene targeted therapies...
4.
Patel M, Johnson M, Winer I, Arkenau H, Cook N, Samouelian V, et al.
Cancer Immunol Immunother
. 2024 Mar;
73(5):89.
PMID: 38554156
Background: Ezabenlimab (BI 754091) is a humanised monoclonal antibody targeting programmed cell death protein-1. We report results from open-label, dose-escalation/expansion, Phase I trials that evaluated the safety, maximum tolerated dose...
5.
Chua K, Kronstedt S, Kaldany A, Srivastava A, Doppalapudi S, Liu H, et al.
Cancer Rep (Hoboken)
. 2024 Jan;
7(2):e1932.
PMID: 38189893
Background: Immuno-oncology therapy (IO) is associated with a variety of treatment-related toxicities. However, the impact of toxicity on the treatment discontinuation rate between males and females is unknown. We hypothesized...
6.
Tchelebi L, Winter K, Abrams R, Safran H, Regine W, McNulty S, et al.
Int J Radiat Oncol Biol Phys
. 2023 Aug;
118(1):107-114.
PMID: 37598723
Purpose: NRG/Radiation Therapy Oncology Group 0848 is a 2-step randomized trial to evaluate the benefit of the addition of concurrent fluoropyrimidine and radiation therapy (RT) after adjuvant chemotherapy (second step)...
7.
Johnson M, Patel M, Aljumaily R, Jones S, Burris Iii H, Spigel D
Oncologist
. 2023 May;
28(7):640-e559.
PMID: 37129455
Background: This was an open-label, multicenter, single-arm phase Ib dose-escalation study of oral LCL161 administered in combination with oral topotecan in patients with relapsed/refractory small cell lung cancer (SCLC) and...
8.
Keruakous A, Asch A, Aljumaily R, Zhao D, Yuen C
Transpl Immunol
. 2022 Jan;
71:101544.
PMID: 35093506
Introduction: Natural killer cells are a potent effector lymphocyte subset that can induce cytotoxicity without the need for antigen sensitization or presentation. NK cells are a tempting target -for immune...
9.
Moore K, Hong D, Patel M, Pant S, Ulahannan S, Jones S, et al.
Target Oncol
. 2021 Sep;
16(5):569-589.
PMID: 34559360
Background: The checkpoint kinase 1 (CHK1) inhibitor prexasertib exhibited modest monotherapy antitumor activity in prior trials, suggesting that combination with chemotherapy or other targeted agents may be needed to maximize...
10.
Moreno V, Garrido P, Papadopoulos K, De Miguel Luken M, Gil-Martin M, Aljumaily R, et al.
Lung Cancer
. 2021 Apr;
155:151-155.
PMID: 33831732
Objectives: Blockade of programmed cell death-1 (PD-1) and its ligand (PD-L1) has transformed the treatment of NSCLC. In a first-in-human, Phase 1, dose escalation and cohort expansion study, cemiplimab, a...